Harrow Health, Inc. (NASDAQ:HROW) Q2 2022 Earnings Conference Call August 9, 2022 4:45 PM ET

Company Participants

Jamie Webb – Director of Communications and Investor Relations

Mark Baum – Chief Executive Officer and Chairman of the Board

Andrew Boll – Chief Financial Officer

Conference Call Participants

Destiny Buch – Ladenburg Thalmann

Sahil Kazmi – B. Riley Securities

Nathan Weinstein – Aegis Capital

Brooks O’Neil – Lake Street Capital Markets

Operator

Good afternoon, and welcome to Harrow Health’s Second Quarter 2022 Earnings Conference Call. My name is Ian, and I will be your conference operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-session.

As a reminder, this conference is being recorded. I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow Health. Please go ahead.

Jamie Webb

Thank you, operator. Good afternoon, and welcome to Harrow Health’s second quarter 2022 earnings conference call. Before we begin today, let me remind you that the company’s remarks may include forward-looking statements within the meaning of Federal Securities Laws.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow Health’s control, including risks and uncertainties described from time in its SEC filings, such as the risks and uncertainties related to the company’s ability to make commercially available its FDA-approved products and compounded formulations and technologies, and FDA approval of certain drug candidates in a timely manner or at all.

For a list and description of those risks and uncertainties, please see the Risk Factors section of the company’s most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. Harrow Health’s results may differ materially from those projected.

Harrow disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of today.

Additionally, Harrow will refer to non-GAAP financial metrics, specifically adjusted EBITDA and/or adjusted earnings, as well as core results such as core gross margin, core net income, and core diluted net income per share. A reconciliation of any non-GAAP measures with the most directly comparable GAAP measures is included in the company’s earnings release and letter to stockholders, both of which are available on the website.

By now you should have received a copy of the earnings press release. If you have not received a copy, please go to the Investor Relations page of the company’s website, www.harrowinc.com. Joining me on today’s call are Harrow’s Chief Executive Officer, Mark L. Baum; and Harrow’s Chief Financial Officer, Andrew Boll.

With that, I’d like to turn the call over to Mark to go over some prepared remarks prior to the question-and-answer session.

Mark Baum

Thanks, Jamie, and thanks to everyone for joining us on today’s call. Our second quarter 2022 earnings release, our corporate presentation, and our letter to stockholders have all been posted to the Investor Relations section of our website, and I would encourage you to review them for a better understanding of the company’s results.

I’d like to start by saying that I’ve been looking forward to having this conference call for quite some time. You might say why? Well, First, we do have strong numbers to report and business does remain good even in-light of the fact that this summer is traditionally a slower time for eyecare, including surgical, with some doctors and staff taking vacations. But second, we are officially in the back half of 2022. This is a period of great consequence for Harrow and a period that I believe will yield some of the most transformative and hopefully financially valuable events in our 10-plus year history.

Before we take your questions on the [Q] [ph] and the stockholder letter, I’d like to provide some highlights of our results from the second quarter ended June 30, 2022. Second quarter revenues of $23.3 million represent a 29% increase over the prior year quarter and a 5% increase over the first quarter of 2022. And this makes the second quarter our eighth consecutive quarter of records and many key financial metrics, including top line revenues.

Second quarter gross profit was also a record that was $16.8 million, that’s a 22% increase over gross profit for the year earlier period of $13.7 million and a 4% increase over the sequential first quarter of 2022. Core gross margin for the second quarter of 2022 was 73% compared with the prior year’s 76%.

Adjusted EBITDA was $4.5 million for the second quarter of 2022, compared with $5.7 million in the prior year period. Core net income was $254,000 for the second quarter of 2022, compared with core net income of $2.1 million in the second quarter of 2021 and core diluted net income per share for the second quarter of 2022 was a penny per share, compared with $0.07 per share during the same period last year.

We did make great progress during the first half of 2022 in terms of the implementation of our strategic plan, which included ensuring that Harrow as an eyecare platform had infrastructure, the systems, the resources and talent needed to execute on the growth that we expect in our compounded pharmaceuticals business, and of course, the new and even more dramatic growth that we expect from the continued integration of FDA approved branded pharmaceutical products onto the Harrow platform, but there is no free lunch in terms of paying for the investments that are required to take advantage of these future highly lucrative sources of revenue, I am happy to say though that we can utilize profits that we’ve made in our core business to make these modest investments without the need to sell equity and dilute our shareholders.

And I can assure Harrow shareholders that we expect the proverbial juice, if you will, in other words, the value that we expect to derive to nearly certainly be worth the squeeze in terms of the investment cost. And here are a few additional items to be on the lookout for during the second half of 2022.

First, and certainly probably the most important thing I would be on the lookout for, and that is our PDUFA target action date of October 16 for AMP-100. This is our patented ocular surface anesthetic drug candidate. Our team is very excited to get this product approved, and into the hands of surgeons early next year, so that patients including those receiving intravitreal injections, and those undergoing various eye surgeries such as cataract surgery can begin to benefit from the unique and clinically important attributes of AMP-100.

Second, at the American Academy of Ophthalmology Conference this September, we expect to launch an exciting new patent pending fortified antibiotic product family. This is something that we’ve been working on for several years. It’s totally unique in the market. It’s proprietary and we are very excited about our launch at the AAO meeting next month.

Third, later this year, we intend to launch a new patent pending formulation suite to address a large and growing chronic care condition. This product family has actually been in the market. We have been perfecting this offering over the last year or so and I am excited about this launch. This will greatly benefit this large and growing patient population in the U.S., and financially for Harrow, we believe this has the potential to be a needle mover.

Lastly, we continually evaluate a robust pipeline of acquisition candidates, some of which are in later stages, and although there could be no guarantees could potentially be announced in the second half of this year.

Now, assuming AMP-100 is approved on the PDUFA target action date of October 16 and is launched in early 2023, as we intend, I continue to believe that revenues from branded pharmaceutical products should eclipse revenues from our compounded pharmaceutical products within a couple of years of AMP-100’s launch.

In addition, we expect our gross margins from branded pharmaceutical products will be larger than our compounded pharmaceutical product gross margins and that will in the aggregate result in our overall gross margins floating higher. When you combine these catalysts that we expect in the second half of 2022 to our growing revenues from the re-launch of IOPIDINE and MAXITROL, and advancements at surface and melt and even pharmaceuticals in which we own equity positions, you can understand why we’re very excited about the balance of the year.

Now, let’s take your questions. I will pause to have our operator pull for questions. Operator?

Question-and-Answer Session

Operator

Thank you. [Operator Instructions] And our first question today comes from Jeffrey Cohen of Ladenburg Thalmann. Please go ahead.

Destiny Buch

Hi. This is actually Destiny on for Jeff. Thank you for taking our questions and congratulations on a really great quarter. Just quickly, I wanted to see if you could touch on kind of your TAM? I know in the previous call you had kind of referenced being able to target some new and additional accounts as you launch these branded products. So, how are you looking at the TAM now versus as you launch those products? And then, also kind of related to that is, how are you having to change your marketing strategy or are you having to change your marketing strategy with the addition of these branded products? And are you able to leverage your existing strategies to really optimize penetration awareness, etcetera?

Mark Baum

Thanks for the question, Destiny. And in terms of the addressable market, we really play obviously in two core markets within ophthalmology, that’s surgical and chronic care. And if you break out the surgical market, we are strong in the cataract surgery market. We estimate that we make drug for as many as, but probably one out of every five cataract surgeries in the United States saw a pretty significant market share and then other surgical interventions such as LASIK and our market share in LASIK in terms of participation with a product in those procedures is even higher than in the cataract surgery marketplace.

We estimate that we serve more than half of the LASIK procedures in the market. Then there are other glaucoma surgeries and retinal procedures and so on that we have smaller shares within. Beyond the surgical market, the chronic care market we participate in making medicines that are prescribed for patients to manage glaucoma, dry eye disease, myopia and conditions like that.

The surgical market that we serve today is going to be different than the surgical market or the procedure market that we serve in the future and one key respect. Currently, we really don’t have a presence in the intravitreal injection space. And with AMP-100, we anticipate having a product that will serve patients undergoing those intravitreal injections. And it’s a considerable number patients. You’re talking about north of 8 million and some estimates north of 10 million procedures per year.

Importantly, there appears to be a new medicine for [dry eye] [ph] related macular degeneration geographic atrophy that will come on the market and some people believe that that could significantly increase the number of intravitreal injections. And so, when you think about an addressable market, for us, having a product like AMP-100 approved, if it’s approved, this October creates a meaningful increase in the addressable market that we will serve.

However, I must say that our access to the chronic care space with the medicines that are prescribed that we make for patients managing dry eye disease and glaucoma, that happens to be the fastest part of our growth. And your second question was related to marketing strategy and whether we’re able to leverage the relationships that we have now and the strategy that we currently use and the answer is unequivocally yes. We have a large customer base.

We, you know for the last couple of years, we’ve said it’s been more than 10,000 customers. Those are doctors and hospitals and surgery centers around the United States. We sell into all 50 states, but what’s important is that from a marketing perspective as an example, because we have so many customers, we recently actually did a survey of our existing customer base to determine a few nuances on a marketing strategy that we were going to pursue.

And I think normal marketing costs for a survey like that would probably be north of – somewhere north of six figures, north of $100,000 and we were able to get that information very, very and expensively from our existing customer base. So, there’s a lot of leverage that’s one example, but we do intend to utilize our presence with these customers going forward as we market our branded products.

Destiny Buch

Got it. Thank you. That’s super helpful. I guess just curious, I noticed year-over-year R&D increased a bit? And I’m wondering if you could talk to that a little bit?

Mark Baum

Sure. Andrew, you want to cover those costs specifically?

Andrew Boll

Yes. Happy to. Hey, Destiny. So, most of the new R&D costs are related to the M&A [Technical Difficulty] that we were to file in 2021. So, the new cost for developing MAQ-100, which we had a FDA – we made with the FDA in August to talk about that clinical program. And then the AMP-100 program, as well as some R&D costs around MAXITROL and IOPIDINE, more recently. So, the big driver and the change year-over-year those new costs for the branded products and new drug candidates.

Destiny Buch

Okay, got it. And that kind of segues into my next question on MAQ-100, you just mentioned that you had the meeting, I guess, this month, so few days ago. What did you take away from that meeting? Is there anything you can call out, anything of that nature?

Mark Baum

Well, the meeting itself, I’d say, was very positive. Our intention with the program was to leverage the work that had been done in Japan for the approval of the product in that market. And I think the upshot from the meeting is that we continue to believe that we will have access to a, I would say a very efficient process and an efficient way of getting that product into the U.S. market.

We still need to see the minutes from the meeting and we still need to have conversations with our partners in Japan, which did take place in the next 30 days to 45 days or so, but it was a very positive meeting. I think the FDA is interested in having a product in the market for that indication that is FDA approved.

Destiny Buch

Got it. That’s all very encouraging for sure. Okay. And then I guess lastly, I’m going to ask you about M&A, even though you discussed it a little bit. I know you’re not going to give me any specifics you never do, which is good. I’m curious though if you could talk about some of the areas in your portfolio that you may be looking to maybe expand or fill?

Mark Baum

Yes. So, you’re going to you’re going to see us do what we’ve done in the past. The recent past, we’re going to focus on where we have commercial credibility. And that is the U.S. market, that is the ophthalmology space, that’s the pharmaceutical space and that is within surgery and in the chronic care market.

So, in surgical, we’re talking about perioperative medications and on the chronic side, that is the disease states that I mentioned. And we are very active. Some of these things take longer than we would like, but we are very excited, actually more excited than we’ve ever been about some of the opportunities that we see. And hopefully if things go our way, we’ll be able to announce some of these things sometime in the back half of this year.

Destiny Buch

Great. No, I’m looking for…

Mark Baum

No guarantees, though.

Destiny Buch

Right. Right. We’ll keep our eyes [peeled] [ph] and look forward to that announcement or any announcement. I think that’s all we have for questions. So thank you so much.

Mark Baum

Thank you, Destiny. Thanks to Jeff too.

Operator

Our next question comes from Sahil Kazmi of B. Riley Securities. Please go ahead.

Sahil Kazmi

Hi, good afternoon, Mark. Congratulations on another record quarter on the revenue side. And just a couple of questions from us. First, could you maybe talk about how we should think about core gross margin moving forward with the – both in the context of the one-time inventory purge that we saw this quarter, but also with AMP-100 potentially coming on the market and the expansion of the branded product portfolio?

Mark Baum

Sure. I think in terms of gross margins, obviously, we identified that we had this inventory purge. It was a one-time event. It was a couple of percentage points. Didn’t have any impact on the quality of our product or anything, and then there were some discounts. Gross margins came down a smidge in this period, but I think the upshot is that we’re going to see margins float in this range in the low to mid-70s as they have for the last, I guess, 6 to 8 quarters or so.

Once we have access to AMP-100 and even potentially some of the other products that we’re pursuing on the M&A front, our expectation is that next year as these products begin to hit the market and we get revenues in from those products. And the gross margins from those products we expect to be significantly higher than our current range. Then in the aggregate, our gross margins will begin to float higher.

Not only will revenues increase as I laid out, we expect revenues to more than double within 18 months to 24 months of the launch of AMP-100, but in addition to that, we should see our gross margin profile rise into the [80s] [ph], that is our expectation based on the models that we’ve built.

Sahil Kazmi

Excellent. Thank you. And then could you provide a bit more color on the fortified antibiotics program? To the extent you’re able to disclose, what’s really the target marketing and how do you see this contributing to the ratio between the compounded and branded pharmaceutical revenue?

Mark Baum

Yes. So, this is, well, both of the families that we intend to launch in the back half of the year outside of AMP-100, outside of any of the M&A activity if we’re able to close anything. Those are compounded products. In the case of [indiscernible], this is an opportunity that we’ve been pursuing for several years, fortified antibiotics are used all over the country to treat sight threatening conditions. And unfortunately, there is no FDA approved product.

And so, these formulations are compounded at local pharmacies around the country, if you can get access to them. There is no way for an eye care professional to actually stock the medication. And so, when a patient presents with a sight threatening condition, these eyecare professionals want to have access right then and there to take care of these patients.

And the promise of the formulation that we’ve been able to create and the IP that we have filed will allow an eye care professional for the first time to have in their office a medication, a fortified antibiotic product to prescribe to these patients and make sure that at their office at the time the patient presents, they will be able to know that that medication is on the patient’s eye and that they are being treated for as a set of potentially site threatening condition.

So, that’s the promise of [indiscernible]. It has never been offered before to our knowledge in the U.S. or anywhere in the world. And we’re really excited about this. As I said, this is something that we’ve been working on for years. No one else has it and we’re going to bring it to the market. I kind of call it, it’s sort of like an EpiPen for the eye. We think that the responsible thing for every eyecare professionals to have one of these in their office patients when present so that they can care for those patients. And so, we’re excited about it.

Sahil Kazmi

That’s helpful. Thank you. And maybe just one last one from us, acknowledging that it is a non-controlling equity position, could you just remind us of the progress, particularly across surface ophthalmic, so we saw with the SURF-100 study and really what might be the significance of that moving forward?

Mark Baum

Yes. So, if you look at the stockholder letter, there is on Page 5, a discussion of the SURF-100 study. I’m a member of the Board of Directors of Surface Ophthalmics and so I have information that I’m not supposed to disclose and I won’t disclose, but what we did put in our stockholder letter is a clear statement that the Phase 2 clinical trial that surface conducted, and by the way, this was completely unique study and that they actually studied various active drugs that Surface Ophthalmic owns against the two market leaders and that would be Restasis and Xiidra. And these are very valuable franchises.

And what I did say in this stockholder letter and I’ll repeat now is that the trial results themselves, absolutely exceeded our expectations and I believe and the company believes that surface has a clinically superior medicine relative to all currently approved drugs and known data from drug candidates in development for this highly underserved market. We think that surface is a very valuable asset. The assets that they have are valuable and the company itself is in the discussions with what their next steps might be.

Sahil Kazmi

Excellent. Thanks for taking our questions and looking forward to following the story the rest of the quarter.

Mark Baum

Thank you, Sahil.

Operator

[Operator Instructions] Our next question comes from Nathan Weinstein of Aegis Capital. Please go ahead.

Nathan Weinstein

Hi, Mark, Andrew, and Jamie. Thanks for taking my questions. Congrats on another strong quarter and a very enjoyable and readable shareholder letter, Mark. Maybe just a question about the operations of the business and where you guys are in terms of headcount and facility investment?

Mark Baum

Sure. Thanks for the question Nathan. In terms of our actual headcount at the close of the quarter, Andrew, do you have an idea, I think we’re probably, what, close to 200 folks.

Andrew Boll

Nathan, we crossed a threshold at the end of the quarter over 200 employees.

Mark Baum

So, about 200 people and in terms of the facilities themselves, the expected CapEx, I mean, we do believe that over the next few years, we’ll have to make marginal improvements in the facilities, but we don’t expect our CapEx to be materially different from investments that we’ve made as we’ve built the business. So, nothing extraordinary.

We continue to invest to make sure that we have the capacity to continue to grow the business and invest in robotics and automation and other tools that make the business more efficient and able to scale?

Nathan Weinstein

Great. Thanks. That’s helpful. And then just a broad question I guess in terms of the macro with the supply chain? And did you see anything in the quarter in terms of inflation hitting you any logistical challenges? And then a slightly different subject, anything on the horizon with drug pricing reform that you think could be impactful for the company?

Mark Baum

I’ll take the first or the last question first, if that’s okay. On drug pricing, in terms of policy and legislation, we really don’t see anything that we expect to materially affect what we’re doing. We’re largely a cash pay business, right now, but as you know, we intend to – as we move more into the FDA approved products business, the branded pharmaceuticals product business more and more of our revenue is going to come from imbursement, whether that’s through private or public payers, but what we’ve seen recently with some of the legislation does not cause us to believe that we’re going to see any impact with the market access strategies that we intend to employ that – for products that would be approved or for products that we own that we’re currently executing and access strategies on.

In terms of inflation, what we have seen and I think a lot of other businesses around the country are seeing is, some wage inflation. Anecdotally it seems a little bit harder to get really great people in certain areas of our business. And there’s one exception for us, right now, in particular and that is on the sales side.

I remember when I was at an eye meeting a few years back, there was a company that really wasn’t doing well in the market and all of a sudden, I had many of their salespeople just come up to me and ask me whether or not we had any openings. And I knew that that company was going south and they ultimately did go south and we picked up their people.

On the positive side for us, we are seeing a lot of applicants on the sales side. There seems to be a buzz about what we’re doing, what’s coming as we bring these products on. So, we are getting a lot of great applicants. And so, I think this is a really positive thing for us. But there has been some wage inflation to answer your question.

On the supply chain side, we haven’t had huge impacts in terms of getting access to active pharmaceutical ingredients and supplies on our manufacturing business. So, things have been relatively stable.

Nathan Weinstein

Great. Thank you, Mark. I appreciate the color of those answers. And again, congrats on yet another very strong quarter.

Mark Baum

Thank you so much, Nathan.

Operator

Our next question comes from Brooks O’Neil of Lake Street Capital Markets. Please go ahead.

Brooks O’Neil

Thank you. Good afternoon, guys. I’m just, first particularly excited about the opportunity with AMP-100, you clearly believe that’s going to be a key driver of the business. Can you just talk about the steps you see for the company following your PDUFA date assuming you get a positive response to that and what you need to do to bring the product to market and begin harvesting that opportunity?

Mark Baum

Sure. And it’s always great to speak to you, Brooks. Thank you for the question. So, in terms of the steps following October 16, the PDUFA date for AMP-100, the primary role we needed filled was we needed to hire the world’s greatest market access group and we were really fortunate. As I said, when I was answering Nathan’s question, on the sales side, we’ve had a lot of great folks that have wanted to join the team. And that is also true on the market access side.

So, we have hired, I think, the world’s heavyweight champion market access group and they are hard at work on our market access strategy for AMP-100 should the product become approved. And they will work on that strategy through the fourth quarter and into the first quarter of next year and then hopefully we’ll be ready to begin the sales process at or around the ASCRS meeting in the spring of next year. That’s the current plan.

And between those times, there’s a lot of work that has to be done on the supply chain side of things and in other key areas of the business. And that’s part of what we are investing in. That’s part of what we’re investing some of our profits in, but as I said, we’ve got an incredible sales organization. We’ve got an incredible market success team, great marketing folks, and everybody’s just geared up and ready to go.

Brooks O’Neil

Great. And can you just refresh my memory? Do you plan to manufacture that product yourself or will you have it manufactured in the contract facility?

Mark Baum

We do not manufacture that product, so we will be bringing that in.

Brooks O’Neil

And then I guess, I’m just curious, obviously, in the early years of the company, the Project 15 businesses and the number you created was a substantial focus for you, Mark and Andrew and the team and it seems like the focus has shifted more towards internal efforts and new products, obviously coupled with M&A strategy. So, could you just talk about why you’ve made that shift and what you think it’s going to do for the business and for investors over time?

Mark Baum

Yes. So, part of the reason why we were executing the Project 15 strategy was to take advantage of assets that we had that were in many cases outside of our core competency, which was ophthalmology. We also wanted focused management teams to run those businesses. And then we wanted to certainly capitalize those businesses using external resource. And so, we were able to create Eaton Pharmaceuticals, we also created Surface Ophthalmics, as well as Melt Pharmaceuticals. Those businesses were capitalized and they were deconsolidated from our balance sheet.

Of course, we continue to own equity in those businesses. And in the case of Eaton as an example, we were able to sell about $10 million of our ownership in Eaton in order to help fund the first transaction, M&A transaction that we did with Novartis. So, we have been able to benefit from the work that we did on, you know what we coined is Project 15.

I think for us though, you need to have a cohesive vision. And for us, we always start with the customer experience and we try to work our way backwards to what our product offering is going to be. And for us, when we talk to our customers and our ophthalmic customers, they really wanted us to focus on ophthalmology and to – and that’s what we’ve decided to do. And in that regard, they’ve also said very clearly to us, they not only want the market leading compounded products that we make and offer throughout the United States, but also branded pharmaceutical products.

FDA approved products are the gold standard. And while we make fantastic compounded formulations that are unique and help doctors and patients around the country, we made over 700,000 of them last quarter alone. Our customers want branded pharmaceutical products as well. And so, we’re creating a unified brand, the Harrow brand, a unified offering that will entail both compounded and branded products. And we believe, but as we get AMP approved and as we hopefully complete some of these other transactions that we’re hard at work on, when we look at what the yield will be for our investors, for our stockholders, we really believe strongly that what we’re doing is going to generate such a significant amount of cash in the next couple of years.

We’re not talking about 5, 10 years from now, but beginning next year that we’ll be able to actually begin to start controlling the destiny even of our stock price or have a little bit more control over it by making the shares a little more scarce. I hope that answers your question?

Brooks O’Neil

Well, it definitely answers my question. I’ll just say, I’m impressed by your nimbleness and I appreciate your vision. I’m excited for the future.

Mark Baum

Thank you.

Operator

Ladies and gentlemen, that’s all the time we have for questions today. And we’ll turn the call back over to Mr. Baum for any closing remarks.

Mark Baum

Thank you, operator. In closing, let me say that if I had written down on a piece of paper a couple of years ago where I would like to have been today, our team has essentially gotten us to that place. Today, we’re staring at a massive amount of upside, real leverage, true leverage and the opportunity to generate cash levels that will, I believe, make our stockholders smile in the coming years. This high potential is real, as sure as I woke up in Nashville this morning.

Of course, none of this would be possible without the hard work of the Harrow family, our partners who diligently work alongside us every day, and I sincerely appreciate their commitment, their loyalty, and dedication. Nor would it be possible without the confidence and trust of our stockholders.

I can assure each stockholder that your investment in Harrow is a responsibility that every member of the Harrow family takes seriously as we continue to build a profitable business that’s committed to making great pharmaceutical products, a focus business in the ophthalmology space and we want our products to be accessible and affordable and to take care of the unmet needs of eyecare professionals and their patience. That’s what we’re doing every day.

So, thanks to everyone for attending today’s call and for your interest in Harrow Health. If you have any investor-related questions, please email Jamie Webb, that’s [email protected]. And this will conclude our call. Thank you.

Operator

The call is now concluded. Thank you for attending today’s presentation. You may now disconnect.

Leave a Reply

Your email address will not be published.